No Data
No Data
Analysts' Opinions Are Mixed on These Healthcare Stocks: Fate Therapeutics (FATE), Acumen Pharmaceuticals (ABOS) and DENTSPLY SIRONA (XRAY)
Buy Rating Justified: Acumen Pharmaceuticals' Promising Position in Alzheimer's Treatment Market
Express News | HC Wainwright & Co. Reiterates Buy on Acumen Pharmaceuticals, Maintains $15 Price Target
Acumen Pharmaceuticals' Sabirnetug: A Novel Approach in Alzheimer's Disease Treatment Warrants a Buy Rating
Acumen Pharmaceuticals Inc (ABOS) (Q1 2024) Earnings Call Transcript Highlights: Strategic ...
Q1 2024 Acumen Pharmaceuticals Inc Earnings Call
No Data